Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades Moderna to Perform

Oppenheimer analyst Hartaj Singh downgrades Moderna (NASDAQ:MRNA) from Outperform to Perform.

byBenzinga Newsdesk

August 6, 2021

1 minute read

Oppenheimer analyst Hartaj Singh downgrades Moderna (NASDAQ:MRNA) from Outperform to Perform.

‘Arkansas Marijuana Activists Push For Legalization Ballot Initiative In 2022’ -Marijuana Moment

By Benzinga Newsdesk

Today, 7:07 AM

https://www.marijuanamoment.net/arkansas-marijuana-activists-push-for-legalization-ballot-initiative-in-2022/

ACB

Barclays Maintains Overweight on Sprout Social, Raises Price Target to $72

By Benzinga Newsdesk

Today, 7:07 AM

Barclays analyst Raimo Lenschow maintains Sprout Social (NASDAQ:SPT) with a Overweight and raises the price target from $63 to $72.

SPT

HC Wainwright & Co. Maintains Buy on Portage Biotech, Lowers Price Target to $22

By Benzinga Newsdesk

Today, 7:07 AM

HC Wainwright & Co. analyst Robert Burns maintains Portage Biotech (NASDAQ:PRTG) with a Buy and lowers the price target from $32 to $22.

PRTG

FDA
News

Zynerba Highlights Poster Presentation At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Jun. 11

By Benzinga Newsdesk

Today, 7:07 AM

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and

ZYNE

Oppenheimer Downgrades Moderna to Perform

Related Posts

‘Arkansas Marijuana Activists Push For Legalization Ballot Initiative In 2022’ -Marijuana Moment

Barclays Maintains Overweight on Sprout Social, Raises Price Target to $72

HC Wainwright & Co. Maintains Buy on Portage Biotech, Lowers Price Target to $22

Zynerba Highlights Poster Presentation At Associated Professional Sleep Societies SLEEP 2021 Annual Meeting Jun. 11